Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.

Altered IL-6 signalling and risk of tuberculosis: a multi-ancestry mendelian randomisation study.

Hamilton F. et al, (2024), The Lancet. Microbe

Injectable core-shell microcapsules deliver prime-boost immunisation against malaria in a single shot

Milicic A. et al, (2024)

A comparative immunological assessment of multiple clinical-stage adjuvants for the R21 malaria vaccine in nonhuman primates.

Arunachalam PS. et al, (2024), Sci Transl Med, 16

A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults.

Hanboonkunupakarn B. et al, (2024), NPJ vaccines, 9

Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya

Sang S. et al, (2024)

High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response

Mentzer AJ. et al, (2024), Nature Medicine, 30, 1384 - 1394

The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study.

Schmit N. et al, (2024), The Lancet. Infectious diseases, 24, 465 - 475

Chemical and biological characterization of vaccine adjuvant QS-21 produced via plant cell culture

Lv X. et al, (2024), iScience, 27

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial

Datoo MS. et al, (2024), The Lancet, 403, 533 - 544

Multi-ancestry meta-analysis of host genetic susceptibility to tuberculosis identifies shared genetic architecture

Schurz H. et al, (2024), eLife, 13

A common NFKB1 variant detected through antibody analysis in UK Biobank predicts risk of infection and allergy.

Chong AY. et al, (2024), American journal of human genetics

Mexican Biobank advances population and medical genomics of diverse ancestries.

Sohail M. et al, (2023), Nature

Injectable core-shell microspheres deliver prime-boost immunisation in a single shot

Guyon R. et al, (2023)

Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms.

Reinke S. et al, (2023), Cell reports. Medicine

Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial

Jenkin D. et al, (2023), The Lancet Infectious Diseases, 23, 956 - 964

An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease.

Dold C. et al, (2023), Science translational medicine, 15

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial

Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182

Higher antigen occupancy of high avidity CSP serum antibodies associates with protection against human malaria

Li K. et al, (2023), Biophysical journal, 122, 144a - 145a

Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus

Fidler S. et al, (2023), Clinical Infectious Diseases, 76, 201 - 209

A tool for evaluating heterogeneity in avidity of polyclonal antibodies.

Li K. et al, (2023), Frontiers in immunology, 14

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?